Novavax, Inc.
NASDAQNVAX short sellers face maximum pain: utilization at 100%, availability crashed 91% in a week to just 1.6%.
Novavax reports Q1 2026 results on May 8 with one of the most extreme short-side setups in the biotech universe — yet a sharp rally into the print has already squeezed a portion of those bears. The lending market is…
NVAX just delivered one of its cleaner earnings surprises in recent memory — Q1 revenue of $139.5M crushed the $78.3M consensus estimate, and a loss of $0.06 per share came in $0.17 better than expected. The stock…
Snapshot as of 22 Jun 2026
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NVAX — free to start on ORTEX.
Sign up for free →Open NVAX on ORTEX